![TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination - ScienceDirect TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842820301256-gr1.jpg)
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination - ScienceDirect
![Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS‐ 102) | Semantic Scholar Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS‐ 102) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1574e38909cc231b8f7b371096b24e3640983a36/2-Figure1-1.png)
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS‐ 102) | Semantic Scholar
![TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo](https://www.medkoo.com/uploads/product/TAS-102__Trifluridine_Tipiracil_HCl_/image/TAS-102.gif)
TAS-102 | Trifluridine | Tipiracil | CAS#733030-01-8 | CAS#183204-74-2 | CAS#70-00-8 | Thymidine Phhosphorylase Inhibitor | Cytotoxic Pyrimidine Analog | MedKoo
![Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer - ScienceDirect Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419320137-gr1.jpg)
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer - ScienceDirect
![Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/41/4/2157/F1.large.jpg?width=800&height=600&carousel=1)
Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer | Anticancer Research
![TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/cc4083cd-2659-41e7-9bce-cf5c88cf963f/gr1_lrg.gif)
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial - The Lancet Oncology
![Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram](https://www.researchgate.net/publication/256470080/figure/fig5/AS:202889797607434@1425384105739/Mode-of-action-of-TAS-102-a-a-a-Trifluorothymidine-FTD-is-converted-by-TK-to-its.png)
Mode of action of TAS-102. α,α,α-Trifluorothymidine (FTD) is converted... | Download Scientific Diagram
![LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy](https://www.lonsurfhcp.com/Content/img/mCRC/lonsurf-mcrc-reduced-mortality-risk-mobile.png)
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
![Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation](https://gastriccancer.org/wp-content/uploads/2018/11/680522_IMG_173101_HR.jpg)
Gastric Cancer Foundation FDA Grants Priority Review to TAS-102 for Gastric/GEJ Cancer | Gastric Cancer Foundation
![Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/38/4/2419/F1.large.jpg)
Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer | Anticancer Research
![TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies - ScienceDirect TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0163725821000255-gr1b.jpg)
TAS-102: A resurrected novel Fluoropyrimidine with expanding role in the treatment of gastrointestinal malignancies - ScienceDirect
![Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO. - ppt download Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO. - ppt download](https://slideplayer.com/slide/13799953/85/images/2/TAS-102+in+Metastatic+CRC.jpg)
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO. - ppt download
![Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies - Godefridus J. Peters, 2015 Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies - Godefridus J. Peters, 2015](https://journals.sagepub.com/cms/10.1177/1758834015603313/asset/images/large/10.1177_1758834015603313-fig2.jpeg)
Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies - Godefridus J. Peters, 2015
![Trifluridine/tipiracil hydrochloride mixture (TAS-102) | Nucleoside Antitumour Agent | MedChemExpress Trifluridine/tipiracil hydrochloride mixture (TAS-102) | Nucleoside Antitumour Agent | MedChemExpress](https://file.medchemexpress.com/product_pic/hy-16478.gif)
Trifluridine/tipiracil hydrochloride mixture (TAS-102) | Nucleoside Antitumour Agent | MedChemExpress
![JCM | Free Full-Text | Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study JCM | Free Full-Text | Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study](https://www.mdpi.com/jcm/jcm-12-00596/article_deploy/html/images/jcm-12-00596-g001.png)